Session 1: Pancreatic Cancer
Chairperson: Michael Choti, MD |
|
Role for Local/Regional Therapy in Advanced Disease |
|
Case 1: Borderline PDAC with Arterial Abutment
Mekhail Anwar, MD (Mentor); Matthew Susko, MD (Fellow)
|
|
Case 3: Case of Advanced PDAC, Progression and Carcinomatosis Beyond First Line Therapy
Davendra Sohal, MD (Mentor); Meena Sadaps, MD (Fellow)
|
Session 2: Hepatobiliary Cancer
Chairpersons: Michael Choti, MD; Ghassan Abou-Alfa, MD |
|
Managing Incidental Gallbladder Cancer
Shishir K. Maithel, MD
|
|
Adjuvant Therapy for Cholangiocarcinoma: Chemoradiation is Best
Edgar Ben-Josef, MD |
|
Case 3: Multidisciplinary Management of Distal Cholangiocarcinoma
Michael Choti, MD (Mentor); Atuhani Burnett, MD (Fellow)
|
Session 3: Esophageal/Gastric Cancer
Chairpersons: Weijing Sun, MD; Nataliya Uboha, MD |
|
Preoperative CROSS is the Preferred Treatment for Locally Advanced GEJ
Nataliya Uboha, MD |
|
Current Status and Future Directions of Targeted Agents and Immunotherapy in Gastric Cancer
Yung-Jue Bang, MD
|
|
Genomic Profiling and Biomarker Guided Therapy in Esophagogastric Cancer
Samuel Klempner, MD
|
|
Proffered Paper
TAGS: A Phase 3, Randomized, Double-Blind Study of Trifluridine/Tipiracil (TAS-102) vs Placebo in Patients with Refractory Metastatic Gastric Cancer
Ben George, MD |
|
|
Friday, November 2, 2018 |
Session 4: Hot Topics in Gastrointestinal Oncology
Chairpersons: Axel Grothey, MD, Howard Hochster, MD |
|
Immuno-oncology - Beyond PD1 Single Agent
Michael Overman, MD
|
|
Cellular Therapies: Wishful Thinking in GI Cancer?
Jaffer Ajani, MD
|
|
Tumor Mutation Profiling in GI Cancer - Worthwhile or Not?
Howard Hochster, MD
|
|
ESMO Update
Axel Grothey, MD
|
Session 5: Localized/Adjuvant Colorectal Cancer
Chairpersons: Daniel Haller, MD |
|
Duration of Adjuvant Therapy for Colon Cancer
Anthony Shields, MD
|
|
Q & A (5 minutes) |
|
Non-Operative Management of Rectal Cancer
Najjia Mahmoud, MD
|
Session 6: Neuroendocrine Tumors (NET)
Chairperson: Jonathan Strosberg, MD |
|
Endoscopic and Surgical Management of Gastric and Duodenal NETs
Sebastian Maasberg, MD
|
|
High Grade Neuroendocrine Cancers: Should They all be Treated Similarly?
Thor Halfdanarson, MD
|
|
Case 1: Discussion of Treatment Options for NET Progressing on a First-line Somatostatin Analog
Jonathan Strosberg, MD (Mentor); Amr Mohammed, MD (Fellow)
|
Session 7: Advanced Colon Cancer
Chairpersons: Axel Grothey, MD; Al Benson, MD |
|
How to Treat mCRC? Making Sense of all the Data
Axel Grothey, MD
|
|
BRAF Mutated mCRC Specific Considerations for Treatment
Dustin Deming, MD
|
|
Immunotherapy of Anal Cancer
Cathey Eng, MD
|
|
|